The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...

Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are becoming ever more popular among diabetes and obesity care patients. Let's dig into Lilly's ...

Drugmaker Eli Lilly is lowering the prices of the two lowest doses of its weight loss drug Zepbound, but they won't be ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was ...

Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots.

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ... the company for comment. Eli Lilly, the manufacturer of tirzepatide ...

In a press release, drug giant Eli Lilly announced that it's releasing single-dose vials of tirzepatide, the active ingredient in Zepbound and its diabetes sister drug Mounjaro, that customers ...

Let's dig into Lilly's latest move concerning Zepbound, its blockbuster drug for chronic weight management, and assess why now could be a lucrative time to scoop up some shares. Although GLP-1 ...